PF-Atlas › Clinical Trials › NCT04312594

Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis

Jaktinib Hydrochloride Tablets · Phase 2

Registry ID
NCT04312594
Phase
Phase 2
Status
Completed
Drug / intervention
Jaktinib Hydrochloride Tablets
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Start
2020-09-08
Enrollment
91
Locations
1

About this trial

This is a multi-center, randomized, double-blinded, and placebo-controlled phase II study to evaluate the efficacy and safety of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis.

View NCT04312594 on ClinicalTrials.gov →

Explore related

All Jaktinib Hydrochloride Tablets trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT04312594 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.